About Us

Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

A Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Social Media

Bluesky • Facebook • Instagram • LinkedIn • YouTube

Meet the Laser Focus World Team

Editorial

Sales

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology
Recent Quotes
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

New Survey Finds More Than Half of Past U.S. Colonoscopy Patients Wish They Had Known More Information About Colonoscopies Including Prep Medication Options and How To Prepare for the Procedure

By: ACCESSWIRE

Salix Pharmaceuticals Releases Findings from First Colonoscopy Awareness Survey

LAVAL, QC / ACCESSWIRE / March 5, 2024 / Bausch Health Companies Inc. (NYSE: BHC)(TSX:BHC) and its gastroenterology business, Salix Pharmaceuticals, today announced findings from its first colonoscopy awareness and perspective survey conducted in partnership with The Harris Poll. Survey findings come in time for Colorectal Cancer Awareness Month and offer patient perspectives on colonoscopies and the preparation process.

The survey was conducted among 506 U.S. residents aged 45+, including 302 who have had a colonoscopy in the past 5 years and 204 who have not. Survey responses showed that preparing for the procedure is one of the barriers preventing people from getting a colonoscopy, specifically in those who have not had a colonoscopy in the last 5 years. Direct conversations and information about colonoscopy preparation may help overcome barriers as over half (58%) of adults aged 45 years and older who have had a colonoscopy in the last five years report wishing they had known more information before their first colonoscopy - including prep medication options and how to prepare for the procedure.

Additionally, the majority of adults 45 and older surveyed (78%) said they rely on their healthcare provider for information about colonoscopies and the process of colonoscopy preparation. Notably, nearly three quarters (73%) of all adults 45+ said their healthcare provider recommended they get a colonoscopy; however, about a third (34%) said their healthcare provider discussed the different colonoscopy prep medication options with them.

"The findings from this survey underscore the need for greater communication and knowledge-sharing between healthcare providers and their patients about the colonoscopy preparation process," said Nicola Kayel, Senior Vice President, Marketing. "Colorectal cancer is the third most common cancer in the United States, and colonoscopy screening is a critical tool in helping detect colon cancer. These insights help us deliver on our goal to provide doctors with resources and solutions to address patient concerns."

Additional survey findings include:

  • 65% of adults 45+ who have had a colonoscopy in the last 5 years report preparing for the colonoscopy was worse than the actual procedure
  • When thinking about preparing for a colonoscopy, 30% of adults 45+ described themselves as feeling prepared and 58% reported having negative feelings about preparing for a colonoscopy
  • 84% of all adults 45+ surveyed say the amount of colonoscopy prep medication liquid they have to consume is important or somewhat important to them

Additional omnibus research was conducted by The Harris Poll on behalf of Salix Pharmaceuticals among 2,058 adults ages 18 and older. This research found 77% of U.S. adults 18+ who have not had a colonoscopy in the past five years would like more information before having their first colonoscopy.

###

About the Methodology
The survey was conducted online from December 7-15, 2023 in the U.S. by The Harris Poll on behalf of Salix Pharmaceuticals among 506 U.S. residents aged 45+, including 302 who have had a colonoscopy in the past 5 years and 204 who have not. Respondents for this survey were selected from among those who have agreed to participate in The Harris Poll surveys. Additional omnibus research was conducted online from January 2-4, 2024 in the U.S. by The Harris Poll on behalf of Salix Pharmaceuticals among 2,058 adults ages 18 and older. No respondents received a cash incentive for their time. Due to the limitations of this survey, results may not be representative of everyone in the U.S. that has or has not gotten a colonoscopy.

About Harris Insights & Analytics

Since 1956, Harris Insights & Analytics' The Harris Poll has conducted survey research on issues of public opinion, motivations and social sentiments. Partnering with media, nonprofits and universities to deepen their missions and work with businesses to transform their marketing, The Harris Poll is one of the longest running surveys in the U.S.

About Salix

Salix Pharmaceuticals is one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases. For more than 30 years, Salix has licensed, developed and marketed innovative products to improve patients' lives and arm health care providers with life-changing solutions for many chronic and debilitating conditions. Salix currently markets its product line to U.S. health care providers through an expanded sales force that focuses on gastroenterology, hepatology, pain specialists and primary care. Salix is headquartered in Bridgewater, New Jersey. For more information about Salix, visit www.Salix.com and connect with us on Twitter and LinkedIn.

About Bausch Health

Bausch Health Companies Inc. (NYSE: BHC)(TSX:BHC) is a global diversified pharmaceutical company enriching lives through our relentless drive to deliver better health outcomes. We develop, manufacture and market a range of products, primarily in gastroenterology, hepatology, neurology, dermatology, medical aesthetic devices, international pharmaceuticals, and eye health, through our controlling interest in Bausch + Lomb. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. For more information, visit www.bauschhealth.com and connect with us on Twitter and LinkedIn.

###

Investor Contact: Media Contact:
ir@bauschhealth.com Kevin Wiggins
(877) 281-6642 (toll-free) corporate.communications@bauschhealth.com
(908) 541-3785
Gianna Scalera
salixcommunications@bauschhealth.com
(908) 541-2110

SOURCE: Bausch Health Companies Inc.



View the original press release on accesswire.com

More News

View More
Palantir-Snowflake Partnership Could Power the Next AI Breakout
Via MarketBeat
Topics Artificial Intelligence
Tickers PLTR SNOW
Broadcom Secures $460 Price Target, Implying +30% Upside
Via MarketBeat
Tickers AVGO NVDA
Why Intuitive Surgical Is a No-Brainer for Long-Term Investors
Via MarketBeat
Tickers ISRG
Analysts Think These Stocks Could More Than Double
Via MarketBeat
Tickers AAPL SBET SNCR TSQ
Can the SharkNinja Rally Continue? Analysts Think So
Via MarketBeat
Topics Earnings Economy
Tickers GS SN

Recent Quotes

View More
Symbol Price Change (%)
AMZN  216.80
-5.23 (-2.36%)
AAPL  256.17
-6.60 (-2.51%)
AMD  225.74
-12.29 (-5.16%)
BAC  50.48
-1.05 (-2.03%)
GOOG  251.19
-0.15 (-0.06%)
META  725.39
-7.88 (-1.07%)
MSFT  518.32
+0.66 (0.13%)
NVDA  177.32
-3.84 (-2.12%)
ORCL  271.67
-3.48 (-1.26%)
TSLA  430.57
-12.03 (-2.72%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.